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Abstract
The aim of the present study was to determine how mesenchymal stem cells (MSC) could improve bone marrow (BM) stroma
function after damage, both in vitro and in vivo. Human MSC from 20 healthy donors were isolated and expanded. Mobilized
selected CD34+ progenitor cells were obtained from 20 HSCT donors. For in vitro study, long-term bone marrow cultures
(LTBMC) were performed using a etoposide damaged stromal model to test MSC effect in stromal confluence, capability of
MSC to lodge in stromal layer as well as some molecules (SDF1, osteopontin,) involved in hematopoietic niche maintenance
were analyzed. For the in vivo model, 64 NOD/SCID recipients were transplanted with CD34+ cells administered either by
intravenous (IV) or intrabone (IB) route, with or without BM derived MSC. MSC lodgement within the BM niche was assessed by
FISH analysis and the expression of SDF1 and osteopontin by immunohistochemistry. In vivo study showed that when the
stromal damage was severe, TP-MSC could lodge in the etoposide-treated BM stroma, as shown by FISH analysis. Osteopontin
and SDF1 were differently expressed in damaged stroma and their expression restored after TP-MSC addition. Human in vivo
MSC lodgement was observed within BM niche by FISH, but MSC only were detected and not in the contralateral femurs.
HumanMSC were located around blood vessels in the subendoestal region of femurs and expressed SDF1 and osteopontin. In
summary, our data show that MSC can restore BM stromal function and also engraft when a higher stromal damage was done.
Interestingly, MSC were detected locally where they were administered but not in the contralateral femur.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is used to treat
several disorders of the immunohematopoietic system [1–4]. The
conditioning regimen is toxic for both hematopoietic stem cells
(HSC) and BM microenvironment [5,6]. The latter is crucial to
ensure normal hematopoietic engraftment after transplantation
[7–9]. Hematopoiesis requires the cooperation between progen-
itors and a variety of functionally and phenotypically different cell
types that form the bone marrow (BM) stroma. Since BM stroma
plays an important role in homing, engraftment, self-renewal, and
differentiation of HSC, it has been postulated that stromal damage
caused by conditioning regimens may have a profound influence
on engraftment kinetics [10]. MSC are the stromal cell
progenitors, so the addition of third party-MSC (TP-MSC) may
result in better engraftment and hematopoiesis after HSCT. On
the basis of this hypothesis, several clinical trials have been
performed to study whether the co-infusion of MSC along with
HSC could improve hematopoietic engraftment [11,12]. The
mechanisms by which the MSC exert their beneficial effect are not
well understood and the capacity of MSC to engraft in recipient
BM is a matter of controversy. Most studies report a lack of
engraftment of donor MSC suggesting a paracrine effect [13], but
they can eventually be detected [14], especially in cases where
there is considerable stromal damage [15]. From a molecular point
of view, SDF1 and osteopontin have been proposed as main tools
of MSC to regulate hematopoietic engraftment kinetics.
In the first part of this work, we studied the effect of TP-MSC
on the hematopoietic population but our purpose was also to know
the mechanism involved at stromal level. The aim of the present
study was to analyze, both in vitro and in vivo, how MSC can
enhance hematopoiesis acting on the BM microenvironment.
Results
MSC from BM samples could be expanded in all cases. All of
them adhered to plastic surfaces, were capable of differentiating into
adipocytes, osteoblasts and chondrocytes, expressed the antigens
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CD44, CD73, CD90, CD105, and CD166 and were negative for
hematopoietic antigens thus fulfilling the criteria proposed for MSC
definition by the International Society for Cellular Therapy (ISCT)
(Figure 1) [16]. MSC expansion capacity was very variable but this
variability was not related to age or gender.
In vitro MSC lodging assay
To evaluate the capacity of TP-MSC to improve stromas after
etoposide treatment, we assessed the percentage of confluence of
the stromal layer. It was always 100% in untreated cultures, but it
decreased in high-dose etoposide-treated stromas to 37% and 19%
after 5 and 15 days of treatment, respectively. When treated
stromas were cultured with TP-MSC supernatants, the confluence
increased (40% and 46% after 5 and 15 days, respectively) and,
when TP-MSC were added, the confluence improved to 100%. In
the latter group, the capacity of these cells to lodge within the
stromal layer was evaluated by FISH for X and Y chromosomes
because TP-MSC from a mismatched-sex donor were added.
Results are shown in Table 1. TP-MSC were able to lodge in
etoposide-treated stromas and their percentage increased in a
dose-dependent manner.
In vitro osteopontin and SDF-1a expression in MSC
In order to establish whether TP-MSC supernatant could
improve chemotherapy-induced stromal damage, it was added to
MSC that had previously been exposed to etoposide assessing
SDF-1 and OPN expression in MSC. Supernatants were added to
culture plates over 2 days (short-term) or 21 days (long-term).
Regarding SDF1 long-term exposure, control cultures showed
polygonal strongly positive cells that always formed well-defined
clusters surrounded by negative cells (Figure 2A, B). By contrast,
very few cells with either polygonal or fibroblastic shapes were
seen in treated cultures (Figure 2C, D). When TP-MSC
supernatant was added to treated cultures, some small polygonal
positive clusters were once again observed (Figure 2E, F).
In control assays very few cells showed osteopontin when
analyzed by immunofluorescence. However, etoposide-treated
stromas showed higher proportion of positive cells that showed
unusual shapes with long prolongations. After three weeks, control
stromas slight more polygonal cells expressing osteopontin
(Figure 2G, H). By contrast, in treated cultures the number of
cells expressing osteopontin was increased in both round cells as
well as those showing prolongations (Figure 2I, J). This feature was
more evident in treated stromas that also had received TP-MSC
supernatant (Figure 2K, L).
To confirm these findings, western blot for osteopontin was
performed. We found that osteopontin expression was stronger in
treated cultures three weeks after etoposide-treatment, the effect
being greater when cultures also received TP-MSC supernatant
(Figure 2M).
RT-PCR was used to quantify the levels of osteopontin and
SFD1 expression. This data confirmed the previous immunohis-
tochemical findings. Osteopontin expression was stronger in
stromal cells following etoposide treatment (after adding both
medium or TP-MSC supernatant) (Figure 2N). By contrast, SDF-1
expression was decreased after etoposide stromal damage and its
Figure 1. Characterization of human MSC. A) Images from MSC expansion. B) Mean fluorescence intensity of stained MSC (blue) and control
non-stained MSC (green). E) In vitro differentiation of MSC to osteoblasts (a, d), adipocytes (b, e) and chondrocytes (c, f) under control conditions (a, b,
c) or with differentiation medium (d, e, f).
doi:10.1371/journal.pone.0026241.g001
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expression increased after adding TP-MSC supernatant
(Figure 2O).
Human MSC detection in murine BM
With the strategy employed for in vitro lodgment analyses by
FISH (using human sexual chromosomes probes since human
HSC and MSC were sex-mismatched), we were able to identify
three cell types within the recipient BM: murine BM cells (no
signal), human HSC-derived cells and human MSC-derived cells
(Figure 3). In 19 out of 32 samples of murine BM a sufficient
number of MSC for FISH analysis were obtained. In all cases
murine BM cells and human HSC-derived cells could be found
(see Part 1). Nevertheless, we consistently found that human MSC
were exclusively detected by FISH in femurs where they were
previously injected, with no signal in contralateral ones (Table 2).
Osteopontin and SDF-1a expression in murine MSC
In order to study the expression of osteopontin and SDF1a as
relevant molecules involved in the in vivo effect of TP-MSC in
hematopoietic engraftment, we analyzed their expression in
femurs from previously injected mice.
When human mitochondria were stained, we could observe that
human cells were located into the BM cavity of murine femurs,
mainly distributed in the epiphysis and showing a higher number
close to the injected site (inthe epiphysis located close to the knee).
Most human cells showed a round shape, used to locate together
and were negative for osteopontin and SDF1 showing that they
were human hematopoietic cells (Figure 4K). In injected femurs
some cells positive for human mitochondria and for osteopontin
and/or SDF1 could be found (Figure 4A–J).
Only few positive cells for osteopontin were observed and all of
them were from human origin and only were present in the
previously injected femurs. Osteopontin expressing cells showed
fibroblastic shape when they were located in the endosteal surface
of bones (Figure 4J) or a pericyte-like shape if they were around
blood vessels (Figure 4A,G).
Regarding SDF1 expression by human MSC, we could confirm
that in all cases, SDF1 expressing cells were from human origin as
they were also positive for human mitochondria staining. Human
SDF1 positive cells showed fibroblastic or polygonal shape and
could be detected at two levels: some of them were distributed
between hematopoietic cells or close to the endostium
(Figure 4C,F), but other had a clear perivascular distribution
(Figure 4G).
In most cases, human MSC located in the femur endostium,
were positive for both osteopontin and SDF1, but those could
show only SDF1 or both molecules SDF1 and osteopontin. These
cells used to be located near blood vessels in the subendosteal
region.
Discussion
After transplantation, HSC home to the BM microenvironment
where they proliferate and replace the original hematopoietic
system [17]. HSC can self-renew and also give rise to differentiated
cells of various lineages within the BM. Both, self-renewal and
differentiation potential are crucial and tightly regulated. Howev-
er, the mechanisms controlling fate decisions and in vivo behavior
of HSC are only partially understood [18]. The microenvironment
of HSC in the BM supports both the maintenance of the stem cell
pool and the differentiation of HSC [7]. A balance between these
processes is mediated by soluble and membrane-bound cytokines,
extracellular matrix components, and direct cell-to-cell contact.
Conditioning regimens are employed pretransplant to eliminate
malignant or abnormal cells and/or to immunosuppress the
recipient to facilitate hematopoietic stem cell (HSC) engraftment.
The conditioning regimen is known to be able to damage not only
the HSC but also the bone marrow (BM) microenvironment [5,6].
It has been suggested that stromal damage caused by conditioning
regimens or previous chemo-therapy treatments may have a
profound influence on engraftment kinetics [10]. BM MSC
contribute to the regeneration of mesenchymal tissues such as
bone, cartilage, muscle, adipose, and marrow stroma and are
essential in providing support for the growth and differentiation of
primitive hematopoietic cells within the BM niche [19]. They
participate in the marrow stroma function producing a vast array
of matrix molecules, cytokines and growth factors [7,20]. In this
line, it has been hypothesized that the addition of TP-MSC may
result in better engraftment after HSCT, and several trials have
examined whether the co-infusion of MSC and HSC improve this
outcome [11,21]. In a previous part of this work we have
demonstrated that the addition of TP-MSC could increase
hematopoiesis [22]. We have used an in vitro model of stromal
damage based on etoposide treatment and an in vivo model based
on the SCID-repopulating assays to test the effect of TP-MSC in
hematopoietic engraftment. In the current work we also wanted to
know the mechanism involved in the MSC effect at the stromal
level.
The mechanisms by which the MSC exert their beneficial effect
are not well understood and the capacity of MSC to engraft in
recipient BM is a matter of controversy. Most studies report a lack
of engraftment of donor MSC [13], but they can eventually be
detected [14], especially in cases where there is considerable
stromal damage [15]. The first aim of this study was to test in vitro
whether stromal damage could favor the lodging of healthy TP-
MSC in the culture by inducing different degrees of damage
(modifying etoposide concentration) and we observed that TP-
MSC lodging was dose-dependent (Table 1). In order to find out
whether TP-MSC effect requires direct cell-to-cell contact or is
performed by soluble factors through a paracrine effect, TP-MSC
supernatant was added to improve the damaged stroma. This
approach only produced a slight improvement, suggesting that
TP-MSC contact is needed when profound stromal damage has
occurred, although when the damage is moderate, the paracrine
effect of TP-MSC may be enough to produce an improvement.
In order to study the mechanism involved in MSC beneficial
effect, two of the most important molecules involved in the
engraftment and maintenance of HPC as osteopontin (an
osteoblastic molecule involved in the stem cell niche) [23] and
SDF-1a (a chemokine involved in HPC trafficking and engraft-
ment by its receptor CXCR4) [24] were analyzed. In the previous
part of this work, when hematopoietic function was studied, we
could observe that BM stromal damage impairs hematopoiesis at
two levels: on the most immature cells (fewer cobblestone areas)
Table 1. In vitro TP-MSC-lodging capacity.
Etoposide concentration
(mM) % Donor cells
Day 5 Day 15
0 0.1 0.0
50 69.0 67.0
100 97.0 99.0
Results expressed as percentages of TP-MSC counted after FISH staining of sex
chromosomes (n = 10).
doi:10.1371/journal.pone.0026241.t001
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and by decreasing committed progenitors (decreased production of
CFU-GM) [22]. In the present work, we aimed to establish
whether SDF-1 and osteopontin were involved. Some studies have
shown a lack of osteopontin in MSC [25], whereas recent
publications have demonstrated the relevance of this molecule as a
hematopoietic support [26]. In this study a stronger activity was
observed in etoposide-treated BM stroma. This feature could be
interpreted as evidence of a mechanism by which the BM-
damaged stroma preserve the most immature progenitors by
increasing molecules involved in their maintenance. By contrast,
SDF-1a expression was highly disrupted in treated stromas,
suggesting that the SDF-1/CXCR4 axis is affected in damaged
hematopoiesis [27,28]. It has been previously shown that SDF-1
favors hematopoietic engraftment [29]. In our model SDF-1a
expression was not homogeneous, there were some cell clusters
expressing strong activity which could represent hematopoietic
niches([27,30]). The paracrine effect of TP-MSC supernatant on
damaged stromas allowed a slight increase in SDF1 expression,
suggesting a restoration of their hematopoietic support capability.
The strongest expression of SDF-1a, which can act as a
chemotactic factor, was observed in normal cultures in accordance
with the stronger expression of CXCR4 in HPC described in the
previous part of this work. Moreover, the addition of TP- MSC to
damaged stromas could improve the secretion of SDF1a, resulting
Figure 2. SDF-1a and osteopontin in vitro expression by MSC. A) SDF-1 expression in control stromas: positive cluster (on the left) surrounded
by negative cells (right) showing a polygonal shape (B). C) In etoposide-treated stromas SDF-1 expression was weaker and cells had different shapes
(D). E) In treated stromas cultured with TP-MSC supernatant, there was an increase in the number of positive cells, which were polygon-shaped (F).
Regarding osteopontin, in control stromas it was expressed in polygonal cells (G, H). In etoposide-treated stromas, osteopontin expression was
stronger than in controls and was located in unusually shaped cells in standard culture medium (I, J) and it was also high expressed in treated-
stromas cultured with TP-MSC supernatant (K, L). M) As confirmed by western blot, osteopontin expression was lower in untreated stromas than in
etoposide-treated stromas (1 = Control; 2 = Etoposide-treated; 3 = Etoposide-treated+TP-MSC supernatant). Finally, the expression of both molecules
osteopontin (N) and SDF-1 (O) was confirmed by PCR.
doi:10.1371/journal.pone.0026241.g002
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in a higher level of CXCR4 expression, thereby favoring
engraftment.
In order to confirm previous in vitro data a xenotransplantation
model was carried out. Some groups have proposed the use of
MSC, in order to improve engraftment, especially in cases of high
risk of graft failure such as haploidentical transplantation, allo-
immunized patients or cord blood transplantation [11,21,31,32].
When MSC are injected IV, most of them are retained within the
lungs microvasculature. To improve MSC local effect new trials
searching for new routes of administration are being explored
[33,34]. In the HSCT setting, IB injection of hematopoietic
progenitors has been shown to enhance engraftment [35,36]. We
have therefore considered that this route of delivery could be
optimal for MSC administration. Previous data showed that TP-
MSC could increase hematopoietic engraftment but we also
wanted to know the mechanism involved in MSC effect. In fact
there is considerable debate about the capability of MSC to
engraft in recipient BM. In a previous study performed by our own
group MSC engraftment was observed after HSCT, especially in
cases in which considerable stromal damage was suspected [15].
The results of MSC chimerism studies deserve an additional
comment, since due to their IB injection we have detected the
human MSC only in the injected femurs and in a very low
proportion showing that these cells can engraft and remain for
long-time when locally injected. However their low number seems
not to be enough to justify benefit on engraftment based on cell to
cell contact suggesting that MSC may secrete several factors that
enhance HSC lodgement [37].
Also we wanted to know their spatial distribution within the BM
as well as their expression of osteopontin and SDF1. Within the
BM two different niches have been described: the osteoblastic and
the endothelial niche. In our model, human MSC were located in
both, in the femur endostium as a part of the osteoblastic niche
and around blood vessels of the sinusoid niche. Moreover, our
results are in accordance with recent data, which showed that
subendosteal region is also rich in blood vessels suggesting that
endothelial cells might be part of the subendosteal niche forming
together a common niche where both, endosteum and sinusoids
contribute to hematopoiesis.
The osteopontin expression in MSC close to endosteum is an
indicative feature of their osteogenic differentiation capacity as a
member of the osteoblastic niche. It has been previously reported
that osteopontin expression is essential for HSC maintenance. In
our model, its expression by human MSC near endostium could
represent their intend to form an osteoblastic niche, trying to
restore osteoblastic damage secondary to irradiation. Regarding
SDF1 expression, previous data indicate that in BM SDF1 could
be shown by both osteoblasts and endothelial cells. Our data are in
this line showing a population of human MSC in the bone
esdosteal surface that express SDF1 and another population
distributed around blood vessels where endothelial cells are
located. The expression of SDF1 by cells close to blood vessels
could emphasize their affect as a chemotactic factor for HSC.
Nevertheless we could not find human hematopoietic cells close
to these human stromas, they were proliferating in colonies or
groups of human hematopoietic cells but their distribution did not
show any relationship with human MSC. This data, along with the
low number of human MSC detected, could indicate that these
cells contributed to restore mice BM niche after irradiation but not
to create independent human niches and probably their
mechanism of action was based on paracrine mechanisms.
In summary, results of the present study show that chemother-
apy damaged stromas can be restored in vitro by TP-MSC, which
were able to lodge in cases where there is considerable stromal
damage and they could restore SDF1 and osteopontin expression
by a paracrine mechanism. In addition in our animal model
human MSC were detected in murine BM when they were
delivered by IB route, but only in the injected femurs and they can
also favor the hematopoietic engraftment by their expression of
SDF1 and osteopontin.
Materials and Methods
MSC isolation, expansion and characterization
Human MSC were isolated from BM cells from 20 healthy
donors (HD) (8 males/12 females). Their median age was 41 years
(range 30 to 61 years). In all cases written informed consent was
previously obtained according to institutional guidelines in
accordance with and approved by the local Ethics Committee of
the Hospital Universitario de Salamanca. Ten to twenty milliliters
of BM aspirate were taken from the iliac crest under local
anesthesia according to standard institutional procedures. Mono-
nuclear cells (MNC) from BM were obtained by a density gradient
centrifugation (Ficoll-Paque, GE Healthcare Bio-Sciences, AB,
Uppsala, Sweden) and cultured in standard culture medium as
previously described [38].
For osteogenic differentiation, MSC were plated at 56103 cells/
cm2 in a 9.6 cm2 slideflask (Nunc, Roskilde, Denmark), expanded
Figure 3. Example of human MSC detection by FISH. In this case
cells were expanded from murine BM 6 weeks after transplantation
human cells from sex-mismatched donors, female HSC and male MSC
(green for X chromosome and red for Y chromosome).
doi:10.1371/journal.pone.0026241.g003
Table 2. Human in vivo MSC engraftment detected by FISH.
Right femur Left femur
IV CD34+ cells + IB MSC 22 (0–38) -
IB CD34+ cells + IB MSC 28 (0–43) -
Results expressed as median number of human MSC detected by slide (range).
MSC: Mesenchymal stem cells; IV: intravenous injection; IB: intrabone injection.
doi:10.1371/journal.pone.0026241.t002
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up to 80% confluence and then further incubated in specific
osteogenic medium (NH Osteodiff Medium; Miltenyi Biotec,
Bergisch Gladbach, Germany). The medium was replaced every 3
to 4 days. After 10 days, cultures were washed, fixed and alkaline
phosphatase activity was assessed by NBT/BCIP solution staining
(Nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phos-
phate) (Roche, Basel, Switzerland), following manufacturer’s
recommendations.
For the adipogenic differentiation assay, 80% confluent MSC,
seeded previously in a slideflask, were subsequently incubated in
adipogenic medium (NH Adipodiff Medium; Miltenyi Biotec).
The medium was changed twice a week for 21 days. Then, cells
were washed, fixed and adipogenesis was measured by the
accumulation of neutral lipids in fat vacuoles, stained with Oil-
Red-O solution (Certistain Merck KGaA, Darmstadt, Germany).
For chondrocyte differentiation, 56105 cells were placed in a
15-mL polypropylene tube (Corning Incorporated, Corning, NY,
USA) and centrifuged. The pellet was cultured at 37uC and
5%CO2 in 500 mL chondrogenic medium (NH Chondrodiff
Medium; Miltenyi Biotec). Medium was changed every 3 to 4
days. After 21 days of culture, pellets were embedded in paraffin,
cut into 5 mm sections and chondrocyte differentiation was
evaluated by toluidin blue staining (Chemicon International,
Hofheim, Germany).
For immunophenotypic analyses, cells were harvested and
resuspended in PBS. MSC were incubated for 15 minutes with
fluorescein isothiocyanate (FITC)-conjugated CD90, FITC-conju-
gated CD44, FITC-conjugated CD34, phycoerythrin (PE)-conju-
gated CD73, PE-conjugated CD14, PE-conjugated CD166,
phycoerythrin-cyanine 5 (PC5)-conjugated Anti-HLA-DR, PC5-
Figure 4. SDF-1a and osteopontin in vivo expression by human MSC. Human MSC expressing osteopontin and SDF1 could be found close to
femur endostium or around blood vessels when they were analyzed in sequential sections (106) (A–F). In most cases these human cells were positive
for both osteopontin and SDF1 (G–I) (1006), but in some cases they were positive only for osteopontin in endostium (J) (1006) or SDF1 around
blood vessels (L) (1006). Human hematopoietic cells could be detected forming colonies or groups of human mitochondria positive cells negative for
osteopontin and SDF1 (K) (206).
doi:10.1371/journal.pone.0026241.g004
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conjugated CD45, and PC5-conjugated CD19 (all from Becton
Dickinson Biosciences, San Jose, CA, USA) and allophycocyanine
(APC)-conjugated CD105 (R&D Systems, Minneapolis, MN,
USA). Sample acquisition was performed in a FACSCalibur flow
cytometer (Becton Dickinson Biosciences). Calibration of the
instrument was performed prior to data acquisition using
previously well-established protocols. CellQuest software program
(Becton Dickinson Biosciences) was used for the acquisition of
50,000 total events. Data were analyzed using the Infinicyt
software (Cytognos, Salamanca, Spain), as previously described
[39].
Chemotherapy
Using a previously established method, etoposide was added to
induce chemotherapy-stromal damage [40]. Etoposide (Sigma-
Aldrich, Steinheim, Germany) was reconstituted in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich, Steinheim, Germany) at a
concentration of 20 mg/ml and stored at 220uC. Etoposide was
diluted in appropriated medium prior to use. The chemothera-
peutic drug doses were chosen to approximate doses described in
clinical settings of transplantation and high dose chemotherapy
doses [40,41].
In vitro MSC lodging assay
Third-passage confluent MSC were used as a feeder layer in
12.5-cm2 culture flasks (Falcon, Becton Dickinson, Le Pont De
Claix, France) and cultured with LTBMC medium for 3 weeks to
induce stromal differentiation, as previously described [42].
In order to test whether TP-MSC could lodge onto damaged
stromas or if they have a paracrine effect, MSC from a different
sex donor were obtained and used as TP-MSC for a second
inoculum in a separate set of experiments. These experiments
were performed in both control and etoposide-treated cultures at
different concentrations (50 and 100 mM). In parallel, the same
cultures were performed by adding only TP-MSC supernatant for
paracrine effect studies. Cultures receiving a second inoculum of
MSC were analyzed after five days and two weeks to study short-
and long-term lodgment, respectively.
For TP-MSC lodging analyses, cells were harvested and fixed
for FISH studies using sexual chromosomes probes following
standard procedures as described elsewhere [43]. Briefly, slides
containing fixed MSC were denatured in pepsin solution for
10 min at 37uC and dehydrated in sequential incubations of
70%/85%/100% ethanol at room temperature. A 10 ml
hybridization mixture consisting of X (orange) and Y (green)
probes (Vysis-Abbot Laboratories, Downers Grove, IL, USA)
was prepared for each 24 mm2 coverslide. Samples were
incubated for 6 min at 75uC and 20 hours at 37uC. After
hybridization, slides were washed in 50% formamide in 26SSC
(0.3 M NaCl and 0.03 M Na citrate) pH 7.0 at 46uC for 5 min
and once in 26SSC. After washes, 1 mg/ml 49, 6-Diamidine-29 -
phenyl indole, dihydrochloride (DAPI) in PBS was added and
the cells were incubated at room temperature for 5 min. Slides
were viewed with a Leica DMI6000B fluorescence microscope
(Leica Microsystems GmbH, Germany) equipped with camera
system. At least 100 nuclei were scored for each probe and
results were expressed as percentage of cells from second MSC
inoculum.
To determine whether MSC were acting throughout a
paracrine effect, cultures receiving TP-MSC supernatant were
studied during the entire culture period by assessing MSC
confluence. Indirect cell counts were made to determine
confluence.
In vitro immunofluorescence analysis
To establish whether molecules secreted from TP-MSC could
improve SDF-1a and osteopontin expression, either fresh medium
or TP-MSC supernatant was added to etoposide-treated or
untreated stromas (n = 8). In order to test SDF-1a and osteopontin
expression immunofluorescence was used following previously
described methods [44]. Two sets of cultures were analyzed:
stromas from MSC untreated or treated with etoposide. To
establish whether molecules secreted from normal MSC could
improve SDF-1a and osteopontin expression in damaged stromas,
either fresh medium or TP-MSC supernatant for 48 h (short-term)
or 3 weeks (long-term) were added to cultures. The expression of
SDF-1a and osteopontin was measured, as well as the morphology
of stromal cells, to test the effect of TP-MSC supernatant
(paracrine effect of MSC) on damaged stromas. As primary
antibodies, rabbit polyclonal anti-human stromal-derived factor
(SDF-1a) (Abcam, Cambridge, UK) and mouse monoclonal anti-
human osteopontin (Abcam) were used. Cells were fixed with 4%
paraformaldehyde and stained for the previously described
primary antibodies. As secondary antibodies, rabbit anti-mouse
Cy3 for osteopontin detection and goat anti-rabbit Cy2 for SDF-
1a analysis were used. Finally, slides were mounted and observed
with a Leica DMI6000B fluorescence microscope equipped with a
camera system, using the appropriate filter for each fluorescence.
Images were captured and then analyzed using Leica Application
Suite 2.02.
Western blot
Western blot was performed to confirm the results of the
previous analysis of osteopontin expression following methods
described elsewhere [45]. Three weeks after etoposide treatment,
cells were washed with PBS (Gibco, Invitrogen, Paisley, UK) and
lysed in ice-cold lysis buffer (140 mM NaCl, 10 mM EDTA, 10%
glycerol, 1% Nonidet P-40, 20 mM Tris pH 7.0, 1 mM pepstatin,
1 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mM sodium orthova-
nadate). Fifty micrograms of the protein samples were subjected to
12% SDS/PAGE and blotted onto PVDF membrane (Millipore).
Membranes were incubated with mouse anti-osteopontin (1:500)
and mouse anti-tubulin (1:100) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Membrane-bound first-step antibodies were
reacted with horseradish peroxidase-conjugated anti-mouse (GE
Healthcare, Amersham, UK) and bands were visualized with a
luminol-based detection system with p-iodophenol enhancement
[45].
RT-PCR analysis
Real-time quantitative polymerase chain reaction (RQ-PCR)
was performed to confirm the previous analysis of osteopontin and
SDF1 expression in four independent sets of experiments [46].
RNA was isolated with the RNeasy Mini Kit (Qiagen, Valencia,
CA, USA) and quality and quantity were assessed with NanoDrop.
The retrotranscription reaction was performed with a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems
Foster City, CA, USA) according to the manufacturer’s recom-
mendations. RQ-PCR was carried out on cDNA using Assays-on-
Demand gene expression mixes specific for osteopontin and SDF1
(Hs_00167093 and Hs_00171022, respectively) and the TaqMan
Fast Universal PCR master mix (Applied Biosystems). Reactions
were carried out in a StepOnePlus Real-Time PCR System using
20 ng of cDNA in a final volume of 10 mL. RQ-PCR amplification
of the ABL gene was used to assess RNA quality and quantity and
to normalize gene expression in the experiments. The relative
quantification of gene expression was performed using the cycle
threshold increment method.
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Animals
Six weeks NOD.CB17-Prkdcscid/NcrCrl mice were pursached
from Charles River Laboratories (Barcelona, Spain), housed in
microisolator cages and maintained under sterile conditions in the
animal facility of the University of Salamanca. All procedures were
used, following the Spanish and European Union guidelines (RD
1201/05 and 86/609/CEE, respectively) and after the approval of
the local Bioethics Committee of the University of Salamanca
(Reg.Nu 201100007927).
In vivo MSC engraftment
The NOD/SCID mouse xenotransplant model was established
as previously reported, with slight modifications [47]. A total of 64
mice were used for this experiment. Eight weeks old mice were
exposed to 300-cGy total body irradiation from a CS source
(Gammacell-200, Nordion International, Ottawa, ON, Canada).
Six to eight hours after irradiation, the animals were anesthetized
with a mixture of ketamine (90 mg/kg; Imalgene 500, Merial,
Lyon, France) and xylazine (10 mg/kg; Rompun 2%, KVP
Pharma, Bayer Healthcare, Kiel, Germany) for transplantation. In
order to test the role of the injection site of hematopoietic cells and
MSC in hematopoietic engraftment, human HSC cells were
intravenous (IV) or intrabone marrow (IB) administrated while
human MSC were exclusively IB injected under the following
conditions: 1) 26106 IV CD34+ cells; 2) 26106 IV CD34+ cells
and 56105 IB MSC; 3) 26106 IB CD34+ cells; 4) 26106 IB
CD34+ cells and 56105 IB MSC and sixteen mice were included
in each experimental group. In all cases, CD34+ cells and MSC
were obtained from a sex-mismatched donor. Intravenously
injected cells were resuspended in a 200 ml of PBS and slowly
injected by the tail vein. For IB injection, a 27-gauge needle was
inserted into the joint surface of the right femur, and human cells
were injected into the BM cavity in a total volume of 20 ml. Six
weeks after transplantation animals were killed. Half of mice
femurs from each group were used for MSC expansion and
subsequent human MSC detection by FISH. The other half was
fixed for immunohistochemistry analysis. Both will be explained
next. Hematopoietic engraftment has been previously described in
part one.
Human MSC detection in murine BM by FISH
MNC obtained after 6 weeks from both femurs were seeded in
12-wells culture plates (Corning) under the same conditions
previously described for human MSC expansion. For human
MSC detection, cells were harvested after the second passage and
stained for FISH using human sex chromosome probes as
previously described for in vitro assays. Briefly, a 10-ml hybridiza-
tion mixture consisting in X (orange) and Y (green) probes (Vysis-
Abbot Laboratories, Downers Grove, IL, USA) was prepared for
each 24 mm2 coverslide. Slides were viewed with a Leica
DMI6000B fluorescence microscope. Total nuclei were scored;
results were expressed as total number of human MSC detected by
sample.
Immunohistochemistry analysis in murine femurs
We used immunohistochemistry to test whether SDF-1a and
osteopontin were modified after healthy MSC addition. Murine-
femurs were fixed, paraffin embedded and 5 mm thick tissue
sections were placed on glass slides. Paraffin sections were
deparaffinized and endogenous peroxidase activity was blocked
by immersing the sections in 3% hydrogen peroxide for 5 min.
The sections were then incubated with 5% normal donkey serum
and bovine serum albumin to block nonspecific binding. As
primary antibodies, the previously described anti-SDF-1 and anti-
osteopontin antibodies were used. In order to detect if expressing
cells were from human origin, also a primary antibody for human
mitochondria detection has been used in sequential sections. As
secondary antibodies, biotin-conjugated donkey anti-mouse IgG
for human osteopontin and mitochondria detection and donkey
anti-rabbit IgG for SDF-1a analysis were used (both from Jackson
ImmunoResearch, West Grove, PA, USA). The sections were then
incubated with avidin-biotin-peroxidase complex ABC Elite Kit
PK-6100 (Vector Laboratories, Burlingame, CA, USA) for 30 min
at room temperature. After washing with PBS brown pigmenta-
tion was produced by treatment with 3,39-diaminobenzidine
(DAB) (Sigma, St Louis, MO, USA)
Finally, slides were mounted and observed with an Olympus
BX41TF microscope (Olympus Optical Co., Tokyo, Japan).
Statistical analysis
Medians and ranges were calculated for each variable. The non-
parametric Mann-Whitney U-test was used to estimate the
significance of the differences between groups. Differences were
considered to be significant for values of p,0.05. All statistical
analyses were done with SPSS 17.0 (Chicago, IL, USA).
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